AR035605A1 - Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores - Google Patents
Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptoresInfo
- Publication number
- AR035605A1 AR035605A1 ARP010105640A ARP010105640A AR035605A1 AR 035605 A1 AR035605 A1 AR 035605A1 AR P010105640 A ARP010105640 A AR P010105640A AR P010105640 A ARP010105640 A AR P010105640A AR 035605 A1 AR035605 A1 AR 035605A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- independently selected
- optionally substituted
- halo
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 12
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 6
- 101150047265 COR2 gene Proteins 0.000 abstract 4
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- BSRHATGBRQMDRF-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-2-ylmethanamine Chemical class C1=CC=C2OC(CN)CCC2=C1 BSRHATGBRQMDRF-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Derivados aminometilcromanos disustituidos, que comprenden un compuesto de fórmula (1) en la cual: R es hidroxi, oxo, halo, ciano, nitro, alquilo C1-10 opcionalmente sustituido con fenilo, haloalquilo C1-10, CF3, NR1R1, SR1, OR1, SO2R2, OCOR2, NR1COR2, COR2, NR1SO2R2, fenilo, o un heterociclo de 5- o 6- miembros con 1 a 4 heteroátomos seleccionados independientemente desde O, S, y N; cada porción cíclica está opcionalmente sustituida con hidroxi, R1, halo, ciano, NR1R1, SR1, CF3, OR1, cicloalquilo C3-8, NR1COR2, COR2, SO2R2, OCOR2, NR1SO2R2, alquilo C1-10, o alcoxi C1-10; R1 es hidrógeno, (CH2)d-O-(CH2)dR5, donde cada d está seleccionada independientemente, o alquilo C1-10 opcionalmente sustituido con 1 a 4 sustituyentes cada uno independientemente seleccionado de hidroxi, halo, CO2alquilo C1-4, CO2H, S(O)balquilo C1-10, alcoxi C1-10, y fenilo opcionalmente sustituido con CO2alquilo C1-4 o CO2H, o cicloalquilo C3-8, fenilo, o naftilo, cada uno opcionalmente sustituido con 1 a 4 sustituyentes cada uno independientemente seleccionado de halo, nitro, oxo, alquilo C1-10, alcoxi C1-10, y alquiltio C1-10; donde dos grupos R1 está unidos a N como NR1R1, y estos grupos R1 pueden formar conjuntamente con el nitrógeno al cual están unidos un anillo heterocíclico que contiene C4-7, 1 a 2 átomos de N, y 0 a 1 átomos de O ó S; R2 es R1, o OR1, NR1R1, NHS(O)bfenilo opcionalmente sustituido con alquilo C1-4, alcoxi C1-4, halo o nitro; NHS(O)bnaftilo, NHS(O)balquilo C1-10; o un heterociclo de 5- o 6- miembros con uno o más heteroátomos seleccionados independientemente de O, S y N, estando dicha porción heterocíclico opcionalmente sustituida con R1; R3 es hidrógeno, alquilo C1-10, bencilo, o COR2; R4 es hidrógeno, alquilo C1-10, alquilo C1-10-fenilo, alquilo C1-10-piridina; R5 es hidrógeno o COOH; Ar es fenilo opcionalmente fusionado con ciclohexilo, fenilo o un heterociclo de 5- o 6- miembros que contiene uno o más heteroátomos cada uno independientemente seleccionado de O, S y N, estando dicha porción bicíclica opcionalmente fusionada con fenilo, o un heterociclo de 5-o 6- miembros que contiene uno o más heteroátomos cada uno independientemente seleccionado entre N, S y O, opcionalmente fusionado con fenilo; X es O ó S(O)b; Y es halo, R1, OR1, SR1, CO2R1, NR1R1, S(O)b-fenilo-CO2R1, o fenilo opcionalmente fusionado con otro anillo fenilo o un heterociclo de 5- o 6- miembros que contiene uno o más heteroátomos cada uno independientemente seleccionado de N, S y O, o un heterociclo de 5- o 6- miembros que contiene uno o más heteroátomos cada uno independientemente seleccionado entre N, S y O, que están opcionalmente fusionados con un anillo fenilo, estando cada porción cíclica opcionalmente sustituida con uno o más sustituyentes independientemente seleccionados de COR2, halo; OR1, NR1R1, R1, C1-10COR2, fenilo opcionalmente sustituido con halo, alquilo C1-4, o alcoxi C1-4, tetrazolo; o un resto de fórmula (2) en la cual, cuando los dos grupos R4 unidos al mismo C son ambos alquilo, pueden estar opcionalmente unidos de modo que cuando se toman conjuntamente con el C al cual están unidos, forman un anillo espiro de 3, 5, o 6 átomos de C, o cuando el R4 unido a N y un R4 unido al C adyacente son ambos alquilo, pueden estar opcionalmente unidos de modo, que tomados conjuntamente con los átomos a los cuales están unidos forman un heterociclo de 5- o 6- miembros; a es 0, 1, 3, 4 ó 5; b es 0, 1 ó 2; d es 1, 2, ó 3; e es 1 ó 2; y sales y ésteres de los mismos farmacéuticamente aceptables; un método para su preparación, composiciones farmacéuticas y el uso de dichos derivados para la manufactura de medicamentos útiles como agonistas b-3-adreno-receptores que son útiles en el tratamiento de las condiciones intermediadas por el receptor b-3, para tratar diabetes, obesidad, tratamiento de hiperplasia prostática benigna, hipertrigliceridemia, hipercolesterolemia, disminuir niveles de lipoproteína de alta densidad, arteriosclerosis, enfermedades cardiovasculares y enfermedades relacionadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25473500P | 2000-12-11 | 2000-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035605A1 true AR035605A1 (es) | 2004-06-16 |
Family
ID=22965389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105640A AR035605A1 (es) | 2000-12-11 | 2001-12-04 | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6699860B2 (es) |
| EP (1) | EP1343778A2 (es) |
| JP (1) | JP2004524286A (es) |
| AR (1) | AR035605A1 (es) |
| AU (1) | AU2002228816A1 (es) |
| CA (1) | CA2430992A1 (es) |
| HN (1) | HN2001000275A (es) |
| PE (1) | PE20040122A1 (es) |
| SV (1) | SV2003000756A (es) |
| UY (1) | UY27065A1 (es) |
| WO (1) | WO2002048134A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| AU2003248352A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS |
| AU2003209527A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| ATE500827T1 (de) * | 2002-11-07 | 2011-03-15 | Astellas Pharma Inc | Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff |
| US20040097433A1 (en) * | 2002-11-15 | 2004-05-20 | Sekhar Boddupalli | Chroman derivatives for the reduction of inflammation symptoms |
| DE10348257A1 (de) * | 2003-10-16 | 2005-05-25 | Merck Patent Gmbh | Verfahren zur Herstellung von enantiomereneinen in 2-Position substituierten Chromanderivaten |
| KR20060124603A (ko) * | 2003-11-03 | 2006-12-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물 |
| US20050222247A1 (en) * | 2003-12-13 | 2005-10-06 | Bayer Healthcare Ag | Chroman derivatives |
| BRPI0614834A2 (pt) * | 2005-08-18 | 2011-04-19 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e usos destas |
| WO2007051735A1 (en) | 2005-11-03 | 2007-05-10 | F. Hoffmann-La Roche Ag | Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors |
| US20100029689A1 (en) * | 2008-07-02 | 2010-02-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| JP5849947B2 (ja) | 2010-03-29 | 2016-02-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
| KR20190096949A (ko) | 2016-10-05 | 2019-08-20 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 소분자 ampk 활성화제 |
| JP2021042126A (ja) * | 2017-12-27 | 2021-03-18 | 佐藤製薬株式会社 | アリールオキシ化合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3706764A (en) | 1969-04-16 | 1972-12-19 | Yoshitomi Pharmaceutical | Phenethylaminomethyl-chromanones and- thiochromanones |
| US3803176A (en) | 1969-05-09 | 1974-04-09 | Novo Terapeutisk Labor As | Sulfonylurea derivatives |
| GB1499323A (en) | 1974-03-22 | 1978-02-01 | Fisons Ltd | 6-substituted chromones and chromanones |
| ATE25251T1 (de) | 1981-11-12 | 1987-02-15 | Fisons Plc | Anti srs-a carbonsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische formulierungen. |
| EP0091749A3 (en) | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| ZA844519B (en) | 1983-06-24 | 1985-02-27 | Hoffmann La Roche | Dihydrobenzopyran derivatives |
| US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
| DE3411992A1 (de) | 1984-03-31 | 1985-10-10 | Bayer Ag, 5090 Leverkusen | Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| GB8801306D0 (en) | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
| FR2695387B1 (fr) | 1992-09-09 | 1994-10-21 | Adir | Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| NZ265692A (en) | 1993-06-14 | 1997-02-24 | Pfizer | Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions |
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| US5561142A (en) | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| US5541197A (en) | 1994-04-26 | 1996-07-30 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| US5516917A (en) | 1994-06-08 | 1996-05-14 | G. D. Searle & Co. | Leukotriene B4 antagonists |
| JPH08198866A (ja) | 1995-01-20 | 1996-08-06 | Tokyo Tanabe Co Ltd | 新規２−アミノ−１−フェニルエタノール化合物 |
| US5663194A (en) | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| FR2746395B1 (fr) * | 1996-03-22 | 1998-04-17 | Adir | Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP3708624B2 (ja) | 1996-03-27 | 2005-10-19 | キッセイ薬品工業株式会社 | ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体 |
| EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
| WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| ID22273A (id) | 1997-01-28 | 1999-09-23 | Merck & Co Inc | TIAZOL BENZENASULFONAMIDA SEBAGAI AGONIS β UNTUK PENGOBATAN DIABETES DAN OBESITAS |
| US6051586A (en) | 1997-12-19 | 2000-04-18 | Bayer Corporation | Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| NZ505200A (en) | 1997-12-19 | 2002-09-27 | Bayer Ag | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-12-04 AR ARP010105640A patent/AR035605A1/es unknown
- 2001-12-07 JP JP2002549665A patent/JP2004524286A/ja not_active Withdrawn
- 2001-12-07 US US10/008,928 patent/US6699860B2/en not_active Expired - Fee Related
- 2001-12-07 CA CA002430992A patent/CA2430992A1/en not_active Abandoned
- 2001-12-07 AU AU2002228816A patent/AU2002228816A1/en not_active Abandoned
- 2001-12-07 EP EP01989934A patent/EP1343778A2/en not_active Withdrawn
- 2001-12-07 WO PCT/US2001/046623 patent/WO2002048134A2/en not_active Application Discontinuation
- 2001-12-10 HN HN2001000275A patent/HN2001000275A/es unknown
- 2001-12-10 SV SV2001000756A patent/SV2003000756A/es unknown
- 2001-12-11 UY UY27065A patent/UY27065A1/es unknown
-
2002
- 2002-06-07 PE PE2002000489A patent/PE20040122A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US6699860B2 (en) | 2004-03-02 |
| UY27065A1 (es) | 2002-07-31 |
| WO2002048134A2 (en) | 2002-06-20 |
| CA2430992A1 (en) | 2002-06-20 |
| HN2001000275A (es) | 2003-10-17 |
| EP1343778A2 (en) | 2003-09-17 |
| WO2002048134A3 (en) | 2003-02-06 |
| SV2003000756A (es) | 2003-01-13 |
| AU2002228816A1 (en) | 2002-06-24 |
| JP2004524286A (ja) | 2004-08-12 |
| US20030078258A1 (en) | 2003-04-24 |
| PE20040122A1 (es) | 2004-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035605A1 (es) | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores | |
| AR035858A1 (es) | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR112822A2 (es) | Método con inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR057769A1 (es) | Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas | |
| AR018187A1 (es) | Derivados de 1,4-dihidro-1,3-diazinas y 3,4-dihidro-1,3-diazinas, procedimiento para su preparacion, medicamentos, procedimiento para la produccion de los mismos y el uso de los mismos para la produccion de medicamentos | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR082391A1 (es) | Inhibidores biciclicos de acetil-coa y usos de los mismos | |
| AR036716A1 (es) | Un compuesto derivado de bencimidazolidinona, metodos que lo utilizan, una composicion farmaceutica que lo comprende y uso de dicho compuesto o composicion | |
| AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
| AR019478A1 (es) | Ligandos derivados de piperidina de alta afinidad para el receptor de nociceptina orl-1, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos. | |
| AR033306A1 (es) | Compuestos | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR047557A1 (es) | Compuestos derivados de piridazina y su uso como agentes terapeuticos | |
| AR044514A1 (es) | Acidos carboxilicos alfa sustituidos como moduladores ppar | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| AR051089A1 (es) | Compuestos de triazoloquinoleina y triazolonaftiridina sustituidas | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR048717A1 (es) | Derivados de acido hexenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas | |
| AR054000A1 (es) | Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |